三菱日联增持了 Incyte 的股份，尽管这家生物制药公司最近的收益低于预期。 Mitsubishi UFJ increased its stake in Incyte, despite the biopharm's recent earnings miss.

三菱UFJ资产管理有限公司通过购买13 026股(目前持有248 875股,价值1 733万美元),增加了其在生物制药公司Incyte公司的股权。 Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in biopharmaceutical company Incyte Corp. by purchasing 13,026 shares, now holding 248,875 shares valued at $17.33 million. 尽管缺少收入预期,但据报EPS为1.09美元,而估计数为1.57美元,Incyte的库存评级为“稳住”,目标价格为74.88美元。 Despite missing earnings expectations, with a reported EPS of $1.09 compared to estimates of $1.57, Incyte's stock has a "Hold" rating and a target price of $74.88. 该公司侧重于发展治疗血病/肿瘤和炎症的治疗方法。 The company focuses on developing therapeutics for hematology/oncology and inflammation.